This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khan, A. J. Articles by Haffty, B. G. Search for Related Content PubMed PubMed Citation Articles by Khan, A. J. Articles by Haffty, B. G.

Characterization of the HER-2/neu Oncogene by Immunohistochemical and Fluorescence in Situ Hybridization Analysis in Oral and Oropharyngeal Squamous Cell Carcinoma

Departments of Therapeutic Radiology [A. J. K., B. L. K., B. D. S., G. L. S., B. G. H.], Medical Oncology [M. P. D.], and Pathology [D. C.], Yale University School of Medicine, New Haven, Connecticut 06520-8040

Purpose: The role of HER-2/neu in squamous cell carcinoma (SCC) of the head and neck is not well defined. The purpose of the current study is to measure the frequency of HER-2/neu expression, to demonstrate HER-2/neu gene amplification in the cases found to be positive for protein overexpression, and to investigate the prognostic significance of overexpression and/or amplification in SCC of the head and neck.

Experimental Design: A cohort of 77 patients with SCC of the oral cavity or oropharynx, with stage III or IV disease and uniformly treated with surgical resection and postoperative radiation, served as the primary patient population for the study. Of these, 56 patients had adequate follow-up and paraffin-embedded specimens available for analysis. Median follow-up was 6.1 years. Each of the paraffin-embedded specimens were immunohistochemically stained for HER-2/neu expression and graded for intensity of staining by a pathologist. All cases that demonstrated positive staining by immunohistochemistry were analyzed by fluorescence in situ hybridization (FISH) to assess HER-2/neu amplification status.

Results: Five-year survival for the 56 evaluable patients was 40%, with 25% experiencing local relapse, 18% regional relapse, and 25% distant relapse. The percentage of tumors staining positive for HER-2/neu by immunohistochemistry was 17%. There was no statistically significant correlation between HER-2/neu and T stage, N stage, tumor grade, survival, or disease-free survival. HER-2/neu expression did correlate with vascular endothelial growth factor expression. FISH analysis revealed four cases that were amplified for HER-2/neu. Of note, of the 4 amplified cases, 2 suffered regional relapse, 1 suffered distant metastasis, and all 4 expired by 5 years of follow-up.

Conclusions: This is the first demonstration of HER-2/neu gene amplification by FISH in SCC of the head and neck. FISH validates a previously contested controversial role for HER-2/neu gene overexpression in SCC of the head and neck. The prognostic significance and clinical implications of HER-2/neu expression and amplification in head and neck cancer will require additional studies.

This article has been cited by other articles:

				J. J.-C. Sheu, C.-H. Hua, L. Wan, Y.-J. Lin, M.-T. Lai, H.-C. Tseng, N. Jinawath, M.-H. Tsai, N.-W. Chang, C.-F. Lin, et al. Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma Cancer Res., March 15, 2009; 69(6): 2568 - 2576. [Abstract] [Full Text] [PDF]

				G. FOUNTZILAS, A. BAMIAS, A. KALOGERA-FOUNTZILA, G. KARAYANNOPOULOU, M. BOBOS, E. ATHANASSIOU, K. T. KALOGERAS, C. TOLIS, P. TSEKERIS, P. PAPAKOSTAS, et al. Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck Anticancer Res, February 1, 2009; 29(2): 529 - 538. [Abstract] [Full Text] [PDF]

				W. C. Spanos, A. Hoover, G. F. Harris, S. Wu, G. L. Strand, M. E. Anderson, A. J. Klingelhutz, W. Hendriks, A. D. Bossler, and J. H. Lee The PDZ Binding Motif of Human Papillomavirus Type 16 E6 Induces PTPN13 Loss, Which Allows Anchorage-Independent Growth and Synergizes with Ras for Invasive Growth J. Virol., March 1, 2008; 82(5): 2493 - 2500. [Abstract] [Full Text] [PDF]

				A. A. Molinolo, S. M. Hewitt, P. Amornphimoltham, S. Keelawat, S. Rangdaeng, A. Meneses Garcia, A. R. Raimondi, R. Jufe, M. Itoiz, Y. Gao, et al. Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative Clin. Cancer Res., September 1, 2007; 13(17): 4964 - 4973. [Abstract] [Full Text] [PDF]

				I. Ganly, S. Talbot, D. Carlson, A. Viale, E. Maghami, I. Osman, E. Sherman, D. Pfister, S. Chuai, A. R. Shaha, et al. Identification of Angiogenesis/Metastases Genes Predicting Chemoradiotherapy Response in Patients With Laryngopharyngeal Carcinoma J. Clin. Oncol., April 10, 2007; 25(11): 1369 - 1376. [Abstract] [Full Text] [PDF]

				K. Freier, S. Joos, C. Flechtenmacher, F. Devens, A. Benner, F. X. Bosch, P. Lichter, and C. Hofele Tissue Microarray Analysis Reveals Site-specific Prevalence of Oncogene Amplifications in Head and Neck Squamous Cell Carcinoma Cancer Res., March 15, 2003; 63(6): 1179 - 1182. [Abstract] [Full Text] [PDF]